Category: Press Release

May 19, 2026

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or […]

May 14, 2026

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or […]

May 8, 2026

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification Durham, NC – May 6, 2026 […]

March 25, 2026

Beam Therapeutics Announces Update on BEAM-302

FOR IMMEDIATE RELEASE: Beam Therapeutics announced compelling updated clinical data from the ongoing Phase 1/2 trial of BEAM-302 in Alpha-1 […]

February 23, 2026

FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases

FDA NEWS RELEASE The U.S. Food and Drug Administration today issued draft guidance for sponsors seeking approval for targeted individualized […]

February 3, 2026

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

“We are thrilled with Wave Life Sciences commitment to the Alpha-1 patient community. Their acceleration of regulatory engagement of the […]

January 16, 2026

Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD

PRESS RELEASE SOMERVILLE, Mass., January 12, 2026 /GLOBE NEWSWIRE/ Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic […]

December 17, 2025

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial

“Thank you to the Alpha-1 patients that participated in this important clinical trial, InnovAATe. It is because of the dedication of patients […]

August 20, 2025

Alpha-1 Foundation Launches Innovative New Model for Centralized Detection

The Alpha-1 Foundation (A1F) is excited to announce the formation of AlphaDetect, a new non-profit subsidiary of A1F, to lead a […]

May 9, 2025

A1F Celebrates 30th Anniversary at 2025 ATS

Honoring Three Decades of Research & Collaboration The Alpha-1 Foundation is enthusiastic to join the American Thoracic Society for the […]

May 5, 2025

Alpha-1 Foundation selected as one of the 2025 Best Nonprofits to Work For

FOR IMMEDIATE RELEASE MAY 5, 2025- The Alpha-1 Foundation (A1F) was recently selected as the #2 overall of the 2025 […]

March 27, 2025

Salazar Reintroduces Bill To Expand Home Infusions For Medicare Beneficiaries With Rare Genetic Disease

On behalf of the Alpha-1 Foundation and entire patient community, we are thrilled with the announcement of the reintroduction of […]

January 31, 2025

The Alpha-1 Foundation Commemorates its 30th Anniversary

The Alpha-1 Foundation (A1F) is proud to commemorate its 30th anniversary of supporting patients with Alpha-1 Antitrypsin Deficiency (Alpha-1) while […]

December 2, 2024

AlphaNet Honors Past Chair Robert L. Greene, Jr. with $100,000 Donation to Alpha-1 Foundation

In recognition of his dedicated service to our Board and Alpha-1 Community, AlphaNet is proud to honor Immediate Past Chair […]

October 31, 2024

“The Power to Connect”: November is Alpha-1 Awareness Month!

Each year, the Alpha-1 Foundation recognizes November as Alpha-1 Awareness Month in order to raise awareness for Alpha-1 Antitrypsin Deficiency […]

August 6, 2024

C-Path Welcomes New Advisory Membersto Alpha-1 Antitrypsin Deficiency Consortium

Critical Path Institute’s (C-Path) Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) consortium today announced the addition of several key advisory […]

April 29, 2024

Grifols Celebrates 50th Anniversary of its Flagship Site

On April 18th, the Alpha-1 Foundation was proud to celebrate Grifols 50th anniversary of its flagship site in Clayton, NC. Grifols […]

February 20, 2024

Celtic Connection 2024

Traditional Irish Stick Fighting demonstration at Alpha-1 Fundraiser

Saturday, March 9, 2024 / 7:00 pm- 11:00 PM

Boston Marriott Newton, 2345 Commonwealth Avenue, Newton MA 02466 […]

Read More… from Celtic Connection 2024

November 7, 2023

GLASSIA® (Takeda) Augmentation Therapy Added to the Canadian Blood Services’ Formulary

November 1, 2023 • Alpha-1 Canada Alpha-1 Canada is thrilled to announce that after much deliberation, the Conference of Deputy […]

November 10, 2022

Announcing Andrew A. Wilson MD as the Alpha-1 Foundation’s new Scientific Director

FOR IMMEDIATE RELEASE November 10, 2022- The Alpha-1 Foundation announces the appointment of Andrew A. Wilson, MD as its new […]

April 1, 2022

Introduction of H.R. 7346: John W. Walsh Home Infusion Act in the House of Representatives

FOR IMMEDIATE RELEASE –Today, April 1, 2022, H.R. 7346: John W. Walsh Home Infusion Act will be introduced. This legislation, […]

October 14, 2021

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency

“The update shared this week by Inhibrx on their Recombinant Alpha-1-antitrypsin (INBRX-101) is exciting news for the Alpha-1 Community. The […]

October 8, 2021

CSL Behring announcement on their product Zemaira

Today, the Alpha-1 Foundation received the following communication from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for […]

September 30, 2021

The Alpha-1 Foundation selects new President and Chief Executive Officer

FOR IMMEDIATE RELEASE The Alpha-1 Foundation announces the selection of Mr. Scott Santarella as the new President and Chief Executive […]

About Alpha-1

Find an Alpha-1 Support Group Near You

Living with Alpha-1

Alpha-1 Education

Alpha-1 Research

Join the Alpha-1 Research Registry

Get Involved

Category: Press Release

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

Beam Therapeutics Announces Update on BEAM-302

FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial

Alpha-1 Foundation Launches Innovative New Model for Centralized Detection

A1F Celebrates 30th Anniversary at 2025 ATS

Alpha-1 Foundation selected as one of the 2025 Best Nonprofits to Work For

Salazar Reintroduces Bill To Expand Home Infusions For Medicare Beneficiaries With Rare Genetic Disease

The Alpha-1 Foundation Commemorates its 30th Anniversary

AlphaNet Honors Past Chair Robert L. Greene, Jr. with $100,000 Donation to Alpha-1 Foundation

“The Power to Connect”: November is Alpha-1 Awareness Month!

C-Path Welcomes New Advisory Membersto Alpha-1 Antitrypsin Deficiency Consortium

Grifols Celebrates 50th Anniversary of its Flagship Site

Celtic Connection 2024

GLASSIA® (Takeda) Augmentation Therapy Added to the Canadian Blood Services’ Formulary

Announcing Andrew A. Wilson MD as the Alpha-1 Foundation’s new Scientific Director

Introduction of H.R. 7346: John W. Walsh Home Infusion Act in the House of Representatives

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency

CSL Behring announcement on their product Zemaira

The Alpha-1 Foundation selects new President and Chief Executive Officer

Newly Diagnosed

Healthcare Providers

About Us

Resources

Contact Us

About Alpha-1

Find an Alpha-1 Support Group Near You

Living with Alpha-1

Alpha-1 Education

Alpha-1 Research

Join the Alpha-1 Research Registry

Get Involved

WEBSITE SPONSORS

Newly Diagnosed

Healthcare Providers

About Us

Resources

Contact Us